| 摘要 |
<p>The invention is related to a biphasic solid sustained release once-a-day oral dosage form comprising hydromorphone or a pharmaceutically acceptable salt thereof together with a sustained release carrier, and to the use thereof in the treatment of human patients. The dosage provides a rise in plasma concentration to an initial early peak concentration, followed by a second peak with plateau plasma concentrations.</p> |
